SALT LAKE CITY, Nov. 03, 2025 — Myriad Genetics, Inc. (NASDAQ: MYGN) reported its third-quarter 2025 financial results and reaffirmed its full-year financial guidance. Third quarter revenue was $205.7 million, a 4% year-over-year decrease, but was flat excluding $8.1 million in previously discussed headwinds. Hereditary cancer testing revenue grew 3%, and volume grew 11% year-over-year. Gross margin was 69.9%.
GAAP net loss was $27.4 million, or $0.29 per share; adjusted EPS was $0.00. Adjusted EBITDA was $10.3 million. Myriad Genetics has entered into a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide an innovative global liquid biopsy companion diagnostic testing solution to pharmaceutical companies.
According to Sam Raha, President and CEO, Myriad Genetics’ execution enabled gross margin to be among the best in the industry and again yielded positive adjusted EBITDA. Raha noted the company is executing its strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including a collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay. Changes to organizational structure and capital deployment are expected to support the company in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward.
Matt Scalo, Investor Contact, (801) 584-3532, matt.scalo@myriad.com; Kate Schraml, Media Contact, (224) 875-4493, PR@myriad.com
Source: Myriad Genetics, Inc.
